Caproni M, Volpi W, Giomi B, Torchia D, Del Bianco E, Fabbri P
Department of Dermatological Sciences, University of Florence, Via della Pergola 58, Florence, Italy.
Br J Dermatol. 2006 Dec;155(6):1270-4. doi: 10.1111/j.1365-2133.2006.07548.x.
Some antihistamines are capable of reducing levels of adhesion molecules in wealing tissues of patients with chronic urticaria (CU).
To determine if 6 weeks of therapy with levocetirizine 5 mg once daily would also induce any decrease in serum levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leucocyte adhesion molecule-1 (ELAM-1) or P-selectin in subjects with CU and chronic autoimmune urticaria.
Thirty-six patients with CU (18 with positive and 18 with negative autologous serum skin test) were studied, together with 10 control healthy subjects. All patients received levocetirizine 5 mg daily. Serum soluble cellular adhesion molecule (CAM) levels were determined by immunoenzymatic assay before and after the end of the study period. Disease activity was recorded according to the EAACI/GA(2)LEN/EDF scoring system.
After levocetirizine therapy CAM levels decreased in patients with CU, significantly in the cases of ELAM-1 and P-selectin. Patients' clinical scores improved during regular antihistamine therapy.
Levocetirizine 5 mg daily demonstrated a broad anti-inflammatory effect in patients with CU. The significant decrease in serum levels of ELAM-1 and P-selectin might reflect the inhibitory activity on neutrophil rolling and extravasation towards inflamed skin.
一些抗组胺药能够降低慢性荨麻疹(CU)患者风团组织中黏附分子的水平。
确定对于慢性荨麻疹和慢性自身免疫性荨麻疹患者,每日一次服用5毫克左西替利嗪进行6周治疗是否也会使细胞间黏附分子-1、血管细胞黏附分子-1、内皮白细胞黏附分子-1(ELAM-1)或P-选择素的血清水平有所降低。
研究了36例慢性荨麻疹患者(18例自体血清皮肤试验阳性,18例阴性)以及10名健康对照者。所有患者每日服用5毫克左西替利嗪。在研究期结束前后,通过免疫酶测定法测定血清可溶性细胞黏附分子(CAM)水平。根据欧洲变态反应和临床免疫学会/全球变态反应和哮喘欧洲网络/欧洲皮肤科和性病学会评分系统记录疾病活动情况。
左西替利嗪治疗后,慢性荨麻疹患者的CAM水平下降,其中ELAM-1和P-选择素的下降尤为显著。在常规抗组胺治疗期间,患者的临床评分有所改善。
每日服用5毫克左西替利嗪对慢性荨麻疹患者显示出广泛的抗炎作用。ELAM-1和P-选择素血清水平的显著下降可能反映了对中性粒细胞向炎症皮肤滚动和渗出的抑制活性。